|
Mar 14
|
TAK or DSNKY: Which Is the Better Value Stock Right Now?
|
|
Mar 13
|
Takeda’s $770M deal deepens Big Pharma’s omics push
|
|
Mar 3
|
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
|
|
Mar 3
|
Takeda and Protagonist report topline outcomes from trial of rusfertide
|
|
Mar 3
|
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
|
|
Mar 3
|
Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera
|
|
Mar 3
|
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
|
|
Feb 27
|
Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now?
|
|
Feb 26
|
Takeda broadens its deal with BridGene for up to $770m
|
|
Feb 25
|
EMA approves Takeda’s Takhzyro pre-filled pen option for HAE
|
|
Feb 24
|
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
|
|
Feb 17
|
TAK vs. DSNKY: Which Stock Is the Better Value Option?
|
|
Feb 15
|
Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?
|
|
Feb 14
|
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
|
|
Feb 12
|
BBI announces $31m facility for Shire to enhance asset finance
|
|
Feb 10
|
Are orexins the next golden child of neuroscience?
|